Zacks Investment Research on MSN
Bayer gets FDA priority review for asundexian NDA in stroke prevention
Bayer BAYRY announced that the FDA has accepted its new drug application (NDA) for its investigational, once-daily, oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results